Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1997-10-01
1999-06-22
Carlson, Karen Cochrane
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 772, 435184, C12Q 100, G01N 3353
Patent
active
059142421
ABSTRACT:
Fostriecin and a compounds structurally related to fostriecin diminish myocardial infarction and delay the onset of cell injury in an ischemic heart. There is a strong correlation between myocardial protection and the inhibition of certain serine/threonine protein phosphatases. The present invention is drawn to a method for administering fostriecin as a pharmacological compound to reduce the size of a myocardial infarction. Further, administration of fostriecin is useful also as an adjunct therapy to treatment with thrombolytic agents or angioplasty to limit the size of infarction. The most advantageous feature of the method of the present invention is that administration of fostriecin diminishes infarct volume and cell injury even when added after ischemia conditions occurred. In addition to the use of the method of the present invention for limiting damage due to myocardial infarction, the method of the present invention can be employed to delay damage associated with tissue storage for organ transplantation.
REFERENCES:
R.S. de Jong, et al. Fostriecin: a Review of the Preclinical Data. Anti-Cancer Drugs 1997, vol. 8, pp. 413-418 (1997).
X.W. Guo, et al. Chromosome Condensation Induced by Fostriecin Does Not Require p 34.sup.cdc2 Kinase Activity and Histone H1 Hyperphosphorylation, but Is Associated with Enhanced Histone H2A and H3 Phosphorylation. The EMBO Journal, vol. 14, No. 5, pp. 976-985 (1995).
Duncan T. Ho, et al. The Antitumor Drug Fostriecin Induces Vimentin Hyperphosophorylation and Intermediate Filament Reorganization. Carcinogenesis, vol. 17, No. 5, pp. 967-972 (1996).
Theodore J. Boritzki, et al. Inhibition of Type II Topoisomerase by Fostriecin, Biochemical Pharmacology, vol. 37, No. 21, pp. 4063-4068 (1988).
Hilary Anderson, et al. Topoisomerase II Inhibitors Affect Entry into Mitosis and Chromosome Condensation in BHK Cells, Cell Growth & Differentiation, vol. 7, pp. 83-90 (Jan. 1996).
Wojciech Gorczyca, et al. Induction of DNA Strand Breaks Associated with Aopotosis during Treatment of Leukemias, vol. 7, No. 5, pp. 659-670 (May 1993).
De-Lin Du, et al. Comparative Toxicity of Fostriecin, Hepsulfam and Pyrazine Diazohydroxide to Human and Murine Hematopoietic Progenitor Cells In Vitro, Investigatinal New Drugs, vol. 9, pp. 149-157 (1991).
Michael Roberge, et al. Antitumor Drug Fostriecin Inhibits the Mitotic Entry Checkpoint and Protein Phosphatases 1 and 2A, Cancer Research, vol. 54, pp. 6115-6121 (Dec. 1, 1994).
Armstrong et al. 1992 J Mol Cell Cardiol 24:869-884.
Deutsch et al 1990 Circulation 82:2044-2051.
Cohen et al 1995 Cardiol. Rev. 3(3):137-149.
Roberge et al. 1994 Cancer Res. 54:6115-6121.
Stryer 1991 Biochemistry 2nd Ed. WH Freenan and Company, San Francisco, pp. 818-819.
Downey James M.
Honkanen Richard Eric
Adler Benjamin Aaron
Carlson Karen Cochrane
South Alabama Medical Science Foundation
LandOfFree
Method for diminishing myocardial infarction using protein phosp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for diminishing myocardial infarction using protein phosp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for diminishing myocardial infarction using protein phosp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1707779